$20.610
-0.148 (-0.72%)收盘时
SPTX 同业对比
In the context of the broader market, SPTX competes directly with industry leaders such as NBTX and MNKD. With a market capitalization of $1.11B, it holds a significant position in the sector. When comparing efficiency, SPTX's gross margin of N/A stands against NBTX's 100.00% and MNKD's 69.00%. Such benchmarking helps identify whether Seaport Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Seaport Therapeutics Inc 财务表现
Seaport Therapeutics has shown a significant improvement in its current ratio, rising to 18.00 in Q2 2026 from 0.00 in previous quarters, indicating strong liquidity. However, it reported a net income loss of -62.6 million USD in Q2 2026, which raises concerns about profitability.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。